• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒病 2019(COVID-19):SARS-CoV-2 的生物物理和生物化学方面以及一般特征。

Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics.

机构信息

Department of Biomedical Engineering, Izmir University of Economics, 35330 Izmir, Turkey.

Faculty of Medicine, Izmir University of Economics, 35330 Izmir, Turkey.

出版信息

Prog Biophys Mol Biol. 2021 Sep;164:3-18. doi: 10.1016/j.pbiomolbio.2021.05.007. Epub 2021 May 24.

DOI:10.1016/j.pbiomolbio.2021.05.007
PMID:34033836
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8142027/
Abstract

The coronavirus disease (COVID-19) arises from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which is an enveloped RNA virus. COVID-19 has rapidly spread throughout the world by infecting more than 143 million people and causing 3.04 million deaths worldwide by 22 April 2021, confirmed by the World Health Organization. It caused great concern and pandemic all over the world, therewithal there has not been found any specific and efficient treatment yet. In the current review, we aimed to define the biophysical and biochemical aspects of SARS-CoV-2, including renin-angiotensin-system, cytokine storms, receptor binding, protein structural and functional features, molecular interactions, and conformational changes that take place during viral attachment and entering into human cells. It was also aimed to highlight the general hallmarks of COVID-19, including treatment strategies, diagnosis and even prevention. Thus, this review will serve as an updated comprehensive body of information and discussion on COVID-19 and will help the molecular scientists, biophysicists, clinicians, as well as medical engineers. Thereby, further understanding of COVID-19 will provide novel insights and advances in development of therapeutic potentials and vaccine alternatives as well as in detection of specific targets for diagnosis.

摘要

冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒-2(SARS-CoV-2)引起的,它是一种有包膜的 RNA 病毒。截至 2021 年 4 月 22 日,世界卫生组织确认,COVID-19 通过感染超过 1.43 亿人并在全球造成 304 万人死亡,在世界范围内迅速传播。它引起了极大的关注和大流行,然而,目前还没有发现任何特定的有效治疗方法。在本次综述中,我们旨在定义 SARS-CoV-2 的生物物理和生化方面,包括肾素-血管紧张素系统、细胞因子风暴、受体结合、蛋白质结构和功能特征、分子相互作用以及病毒附着和进入人体细胞过程中发生的构象变化。我们还旨在强调 COVID-19 的一般特征,包括治疗策略、诊断甚至预防。因此,本综述将作为 COVID-19 的最新全面信息和讨论,为分子科学家、生物物理学家、临床医生以及医学工程师提供帮助。由此,对 COVID-19 的进一步了解将为治疗潜力和疫苗替代品的开发以及特定诊断目标的检测提供新的见解和进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/a107c413ec81/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/f56ea075d0dc/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/53d3d0d505bb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/97106a35c5c1/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/a107c413ec81/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/f56ea075d0dc/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/53d3d0d505bb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/97106a35c5c1/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8efa/8142027/a107c413ec81/gr4_lrg.jpg

相似文献

1
Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics.新型冠状病毒病 2019(COVID-19):SARS-CoV-2 的生物物理和生物化学方面以及一般特征。
Prog Biophys Mol Biol. 2021 Sep;164:3-18. doi: 10.1016/j.pbiomolbio.2021.05.007. Epub 2021 May 24.
2
An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.血管紧张素转换酶 2 衍生的七肽 GK-7 可阻断 SARS-CoV-2 刺突蛋白。
Peptides. 2021 Nov;145:170638. doi: 10.1016/j.peptides.2021.170638. Epub 2021 Aug 19.
3
Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).抑制 S 蛋白 RBD 和 hACE2 相互作用以控制 SARS-CoV-2 感染(COVID-19)。
Mini Rev Med Chem. 2021;21(6):689-703. doi: 10.2174/1389557520666201117111259.
4
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).通过中断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与血管紧张素转换酶2(ACE2)之间的相互作用来实现SARS-CoV-2早期进入的潜在治疗方法。
Biochem Pharmacol. 2021 Oct;192:114724. doi: 10.1016/j.bcp.2021.114724. Epub 2021 Aug 8.
5
, and Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion.用于监测 SARS-CoV-2 刺突/人 ACE2 复合物、病毒进入和细胞融合的模型。
Viruses. 2021 Feb 25;13(3):365. doi: 10.3390/v13030365.
6
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
7
SARS-CoV-2, ACE2 expression, and systemic organ invasion.严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)、血管紧张素转换酶 2(ACE2)表达与全身器官侵袭。
Physiol Genomics. 2021 Feb 1;53(2):51-60. doi: 10.1152/physiolgenomics.00087.2020. Epub 2020 Dec 4.
8
Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2.肾素-血管紧张素-醛固酮系统与 SARS-CoV-2 相互作用的内无序观点。
Infect Genet Evol. 2020 Nov;85:104510. doi: 10.1016/j.meegid.2020.104510. Epub 2020 Aug 24.
9
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
10
Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.SARS-CoV-2 刺突蛋白与人 ACE2 受体相互作用的蛋白质结构分析:从构象变化到新型中和抗体。
Cell Mol Life Sci. 2021 Feb;78(4):1501-1522. doi: 10.1007/s00018-020-03580-1. Epub 2020 Jul 4.

引用本文的文献

1
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.新冠疫苗平台概述,重点介绍亚单位疫苗。
Prog Biophys Mol Biol. 2023 Mar;178:32-49. doi: 10.1016/j.pbiomolbio.2023.02.004. Epub 2023 Feb 18.
2
Comparison of the Immune Response in Vaccinated People Positive and Negative to SARS-CoV-2 Employing FTIR Spectroscopy.采用傅里叶变换红外光谱法比较 SARS-CoV-2 阳性和阴性疫苗接种者的免疫反应。
Cells. 2022 Dec 1;11(23):3884. doi: 10.3390/cells11233884.
3
B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection.

本文引用的文献

1
Covid-19: Chinese vaccines may need changes to improve efficacy, admits official.新冠疫情:官员承认中国疫苗可能需要改进以提高效力。
BMJ. 2021 Apr 13;373:n969. doi: 10.1136/bmj.n969.
2
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.202012/1 感染关注的 SARS-CoV-2 变异株的患者的死亡率风险:匹配队列研究。
BMJ. 2021 Mar 9;372:n579. doi: 10.1136/bmj.n579.
3
The Johnson & Johnson Vaccine for COVID-19.强生公司的新冠疫苗。
基于 B 细胞表位的 SARS-CoV-2 荧光量子点生物传感器可实现高灵敏度 COVID-19 抗体检测。
Viruses. 2022 May 12;14(5):1031. doi: 10.3390/v14051031.
4
The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate.新型冠状病毒的人血管紧张素转换酶 2 受体结合域在新城疫病毒的病毒表面表达,作为一种非复制型病毒载体候选疫苗。
PLoS One. 2022 Feb 8;17(2):e0263684. doi: 10.1371/journal.pone.0263684. eCollection 2022.
5
The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural proteins.抑制SARS-CoV-2非结构蛋白的经过验证的小分子的当前状态。
Turk J Biol. 2021 Aug 30;45(4):469-483. doi: 10.3906/biy-2106-42. eCollection 2021.
6
Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.天然类黄酮对抗 SARS-CoV-2 靶点的有前景的抗病毒活性:系统评价。
Int J Mol Sci. 2021 Oct 14;22(20):11069. doi: 10.3390/ijms222011069.
JAMA. 2021 Apr 20;325(15):1575. doi: 10.1001/jama.2021.2927.
4
mRNA vaccines: A matter of delivery.信使核糖核酸疫苗:递送问题
EClinicalMedicine. 2021 Feb 3;32:100746. doi: 10.1016/j.eclinm.2021.100746. eCollection 2021 Feb.
5
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.美国住院患者预防性抗凝治疗对预防2019冠状病毒病死亡的早期启动:队列研究
BMJ. 2021 Feb 11;372:n311. doi: 10.1136/bmj.n311.
6
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一种灭活严重急性呼吸综合征冠状病毒2疫苗(科兴新冠疫苗)在60岁及以上健康成年人中的安全性、耐受性和免疫原性:一项随机、双盲、安慰剂对照的1/2期临床试验
Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3.
7
Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK.南非严重急性呼吸综合征冠状病毒2变种501Y.V2传入英国。
J Infect. 2021 Apr;82(4):e8-e10. doi: 10.1016/j.jinf.2021.01.007. Epub 2021 Jan 17.
8
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis.严重急性呼吸综合征冠状病毒2刺突蛋白的特征:生物物理、生化、结构和抗原分析
ACS Omega. 2020 Dec 21;6(1):85-102. doi: 10.1021/acsomega.0c03512. eCollection 2021 Jan 12.
9
Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.一种合成 STING 激动剂抑制原代人呼吸道系统中的冠状病毒感染。
Antiviral Res. 2021 Mar;187:105015. doi: 10.1016/j.antiviral.2021.105015. Epub 2021 Jan 12.
10
Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.新型冠状病毒 SARS-CoV-2 主蛋白酶(3CLpro)的生化和生物物理特性分析。
Sci Rep. 2020 Dec 17;10(1):22200. doi: 10.1038/s41598-020-79357-0.